53 Views | 25 Downloads
Susan J. Ramus, Discipline of Women's Health, Adult Cancer Program, Lowy Building Room 219, Level 2, School of Medicine, UNSW Medicine & Health, Sydney, NSW 2052, Australia. Email: s.ramus@unsw.edu.au
Martin Köbel, Department of Pathology and Laboratory Medicine, University of Calgary, 1403 29 ST NW, Calgary, AB T2N 2T9, Canada. Email: mkoebel@ucalgary.ca
Eun‐Young Kang: Immunohistochemical protein and chromogen in situ hybridization scores collection and manuscript draft and revision. Ashley Weir: Analyses. Kyo Farrington: Immunohistochemical protein and chromogen in situ hybridization scores collection. Paul D.P. Pharoah: Statistical advice. Susan J. Ramus: Study conception, design, and supervision. Martin Koebel: Study conception, design, and supervision; immunohistochemical protein and chromogen in situ hybridization scores collection; and manuscript draft and revision. All authors contributed through collection, curation, and maintenance of respective consortia‐based, or local institution, collections of patient samples including recruitment and consenting of patients, clinical care, abstraction of clinical data, and updating of outcome and follow‐up data. All authors revised the manuscript and approved submission of the final version.
The study was funded by Alberta Precision Laboratory research support fund (RS17‐601, RS10‐526). This work was funded by the National Institutes of Health/National Cancer Institute (NCI) grants to S.J. Ramus (grant number R01CA172404). The Australian Ovarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command under DAMD17‐01‐1‐0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; ID199600; ID400413 and ID400281). The AOCS gratefully acknowledges additional support from the Peter MacCallum Foundation and Ovarian Cancer Australia. BGS: Breast Cancer Now and the Institute of Cancer Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. BRZ: Brazilian National Council for Scientific and Technological Development, grant No. 478416/2009‐1; CAL: Cancer Research Society (19319) and CLS Internal Research support RS14‐508; CNI: CNI funded by Instituto de Salud Carlos Tercero (AES grant PI19/01730) and Fondo Europeo de Desarrollo Regional, FEDER. Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012); HOP: Department of Defense (DAMD17‐02‐1‐0669) and NCI (K07‐CA080668, R01‐CA95023, MO1‐RR000056). This project used the UPMC Hillman Cancer Center and Tissue and Research Pathology/Pitt Biospecimen Core shared resource which is supported in part by award P30CA047904. LAX: American Cancer Society Early Detection Professorship (SIOP‐06‐258‐01‐COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; MAY: National Institutes of Health (R01‐CA122443, R01‐CA243483, P30‐CA15083, P50‐CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; NCT: Parts of the study at the NCT were funded by “Heuer Stiftung für medizinische Forschung”; POC: Pomeranian Medical University; SEA: Cancer Research UK C490/A16561, the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Cambridge Cancer Centre. The University of Cambridge has received salary support for Paul D.P. Pharoah from the NHS in the East of England through the Clinical Academic Reserve. TVA: This work was supported by Canadian Institutes of Health Research grant (MOP‐86727) and by NIH/NCI 1 R01CA160669‐01A1; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) with contribution to author’s salary through MRC core funding (MC_UU_00004/01) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre; VAN: BC's Gynecological Cancer Research Team (OVCARE) receives core funding from The BC Cancer Foundation and the VGH and UBC Hospital Foundation; WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 and ID 628903. Cancer Institute NSW Grants 12/RIG/1‐17 and 15/RIG/1‐16. The Westmead GynBiobank acknowledges financial support from the Sydney West Translational Cancer Research Centre, funded by the Cancer Institute NSW; COE: The GYN‐COE program, T.P. Conrads, Y. Cassablanca, G.L. Maxwell, and K.M. Darcy are funded by the U.S. Defense Health Program (grants HU0001‐16‐2‐0006 and HU0001‐19‐2‐0031); The Health Science Alliance (HAS) Biobank, UNSW Sydney, Australia, is funded by the Translational Cancer Research Network (TCRN), a Translational Cancer Research Centre supported by the Cancer Institute NSW. The SWE cohort is funded by the Swedish Cancer Foundation (CAN 2018/384).
For all participating studies, we thank all the women who participated in research, study staff, study participants, physicians, nurses, health care providers, and health information sources who have contributed to the study. We thank Shuhong Liu and Young Ou from the Anatomical Pathology Research Laboratory at the University of Calgary for performing immunohistochemistry and chromogenic in situ hybridization, and Thomas Kryton, image specialist, for compiling the composite figures. We thank the AOCS Study Group (http://www.aocstudy.org); see the supporting information. The contents of the published material are solely the responsibility of the authors and do not reflect the views of the National Health and Medical Research Council of Australia.
S. Ramus is supported by National Health and Medical Research Council of Australia (NHMRC) grant APP2009840. N.S. Meagher is supported by the NSW Ministry of Health and UNSW Sydney under the NSW Health PhD Scholarship Program, and the Translational Cancer Research Network, a translational cancer research center program funded by the Cancer Institute NSW. J. Millstein is funded by NCI grant P30CA014089.
S. Heublein was funded by Heuer Stiftung für medizinische Forschung. M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer Foundation.
BC's Gynecological Cancer Research team (OVCARE) receives support through the BC Cancer Foundation and The VGH+UBC Hospital Foundation. L. Loverix is predoctoral researcher of the Fund for Scientific Research‐Flanders (FWO Vlaanderen 1S41921).
T. Van Gorp is a Senior Clinical Investigator of the Fund for Scientific Research‐Flanders (FWO Vlaanderen 18B2921N).
The funding for K.M. Darcy and preparation of tumor samples and clinical samples are from awards HU0001‐16‐2‐0006 and HU0001‐21‐2‐0027 from the Uniformed Services University of the Health Sciences from the Defense Health Program to the Henry M Jackson Foundation (HJF) for the Advancement of Military Medicine Inc. Gynecologic Cancer Center of Excellence Program (PI: Yovanni Casablanca, Co‐PI: G. Larry Maxwell).
D. Khabele is supported by NIH NCI grants R01CA243511 and R21CA210210. A. Staebler received funding by Deutsche Forschungsgemeinschaft as part of the CRC 685. R.E. was supported by the Interdisciplinary Center for Clinical Research (IZKF; Clinician Scientist Program) of the Medical Faculty FAU Erlangen‐Nürnberg. U. Menon and A. Gentry‐Maharaj are supported by salary contributions through MRC core funding (MC_UU_00004/01).
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.